Based on our secondary screening data, HTR6 is responsible for the Aβ-reducing activity of amoxapine, suggesting that compounds targeting HTR6 may modulate both cognition and Aβ generation, which directly fine-tunes AD pathogenesis. The gene discussed is HTR6; the disease is Alzheimer disease.